Anne‐Emmanuelle Fargeton

Statistics

Publications

Citations

375

H-Index

Active since

2014

Affiliations

Hospices Civils de Lyon(Current)

Université Claude Bernard Lyon 1

Hôpital Femme Mère Enfant

Inserm

Université Grenoble Alpes

Anne‐Emmanuelle Fargeton is an author at Hospices Civils de Lyon specializing in hereditary hemorrhagic telangiectasia, pharmacotherapy, and medicine.

ORCID

Publications per year

2014–2023

Publications

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients

A Guilhem, Anne‐Emmanuelle Fargeton, Anne-Claire Simon et al. · PLoS ONE · 2017 · 81 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +8

Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia

Sophie Dupuis‐Girod, A. Ambrun, Évelyne Decullier et al. · JAMA · 2016 · 72 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

ELLIPSE Study

Sophie Dupuis‐Girod, A. Ambrun, Évelyne Decullier et al. · mAbs · 2014 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial

Sophie Dupuis‐Girod, Sophie Rivière, Christian Lavigne et al. · Journal of Internal Medicine · 2023 · 36 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?

Sophie Dupuis‐Girod, Claire L. Shovlin, Anette Drøhse Kjeldsen et al. · European Journal of Medical Genetics · 2022 · 33 citations · Full text

Medicine, Pharmacotherapy, Surgery +14

1–5 of 11